Monte Rosa Therapeutics

Yahoo Finance • 10 days ago

Here are the top movers in Monday's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT ATCH [https://www.chartmill.com/stock/quote/ATCH/profile] 148.0% ATLASCLEAR HOLD... Full story

Yahoo Finance • 10 days ago

Which stocks are moving on Monday?

Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT ATCH [https:... Full story

Yahoo Finance • 11 days ago

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal

This article first appeared on GuruFocus. Novartis (NOVN, Financials) and Monte Rosa Therapeutics (GLUE, Financials) have signed a deal worth up to $5.7 billion to work together on medicines for disorders that affect the immune system. Un... Full story

Yahoo Finance • 11 days ago

Monte Rosa stock rises after pact with Novartis

[Communication concept] Shares of Monte Rosa Therapeutics (NASDAQ: NASDAQ:GLUE [https://seekingalpha.com/symbol/GLUE]) rose after it announced a new collaboration with Novartis (NYSE:NVS [https://seekingalpha.com/symbol/NVS]) to advance t... Full story

Yahoo Finance • 11 days ago

Monday's session: gap up and gap down stocks

Let's delve into the US markets on Monday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT NAOV [ht... Full story

Yahoo Finance • 11 days ago

Monday's pre-market session: top gainers and losers

Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT GPUS [https://www.chartmi... Full story

Yahoo Finance • 11 days ago

Monte Rosa surges premarket on Novartis collaboration deal

Investing.com -- Monte Rosa Therapeutics shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degra... Full story

Yahoo Finance • 11 days ago

Novartis, Monte Rosa strike $5.7 billion drug development deal

(Reuters) -Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. (Reporting by Kamal Choudhury in Bengaluru; Editing b... Full story

Yahoo Finance • 11 days ago

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa Therapeutics will re... Full story

Yahoo Finance • 11 days ago

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

Monte Rosa Therapeutics, Inc. Novartisreceivesanexclusivelicensetoanundiscloseddiscoverytarget Novartis also receives options to license two programs from Monte Rosa’s growing preclinical immunology portfolio MonteRosatoreceiveanupfront... Full story

Yahoo Finance • last month

Validea Kenneth Fisher Strategy Daily Upgrade Report - 8/12/2025

The following are today's upgrades for Validea's Price/Sales Investor model based on the published strategy of Kenneth Fisher. This value strategy rewards stocks with low P/S ratios, long-term profit growth, strong free cash flow and consi... Full story

Yahoo Finance • 2 months ago

Monte Rosa Therapeutics Inc (NASDAQ:GLUE) Q2 2025 Earnings: Revenue Surges, Loss Narrower Than Expected

MONTE ROSA THERAPEUTICS INC (NASDAQ:GLUE [https://www.chartmill.com/stock/quote/GLUE]) REPORTS Q2 2025 EARNINGS: REVENUE BEATS, EPS NARROWER THAN EXPECTED Monte Rosa Therapeutics Inc posted second-quarter 2025 financial results that excee... Full story

Yahoo Finance • 2 months ago

Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

MRT-8102 Phase 1 study includes single and multiple ascending dose cohorts in healthy volunteers and is designed to evaluate safety, pharmacokinetics, NEK7 protein degradation, and other key downstream pharmacodynamic markers; initial resu... Full story

Yahoo Finance • 3 months ago

Monte Rosa Announces Publication in Science of Key Insights that Enable Next Generation Molecular Glue Degrader Medicines

BOSTON, July 03, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the publication of groundbreak... Full story

Yahoo Finance • 4 months ago

Monte Rosa gets FDA clearance to begin testing MRT-8102

[Life Science Investing] Bill Oxford/E+ via Getty Images * Monte Rosa Therapeutics (NASDAQ:GLUE [https://seekingalpha.com/symbol/GLUE]) said on Tuesday that the U.S. FDA approved the request to start testing its orally active molecular... Full story

Yahoo Finance • 4 months ago

Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases

MRT-8102, a highly selective NEK7-directed molecular glue degrader (MGD) developed to treat inflammatory conditions linked to NLRP3, IL-1β, and IL-6 dysregulation, expands Monte Rosa’s clinical I&I portfolio Potency, selectivity, and long... Full story

Yahoo Finance • 2 years ago

Monte Rosa Therapeutics to Present at Piper Sandler Healthcare Conference

BOSTON, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will participate in a fireside disc... Full story

Yahoo Finance • 2 years ago

Monte Rosa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Interim data from Phase 1/2 clinical trial of MRT-2359 demonstrated tumor reductions in patients with biomarker-positive cancers; recommended Phase 2 dose expected in Q2 2024 Announced strategic collaboration with Roche to discover novel... Full story

Yahoo Finance • 2 years ago

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2023 Demonstrating Potential of MRT-6160, a VAV1-targeted Molecular Glue Degrader, to Treat Immunological and Inflammatory Diseases

Data presented support broad potential therapeutic applications of MRT-6160 in a variety of autoimmune and inflammatory disorders driven by underlying dysregulation of T- and B-cells, including rheumatoid arthritis Investigational New Dru... Full story

Yahoo Finance • 2 years ago

Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced At- the-Market Under Nasdaq Rules

BOSTON, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised $25 million... Full story